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Hydroxyethyl starches in burns
To the Editor: Den Hollander[1] argues that ‘the exclusion of severe 
burns from the indications for the use of colloids, as well as the 
exclusion of consultant surgeons and emergency specialists from 
those who will be allowed to prescribe HES-containing products, 
indicates little insight into the evidence and the clinical situation “at 
the coalface”.’
The author places considerable emphasis on the value of starch 
in light of its volume sparing effect,[1] and there is some support for 
this assertion,[2] but he also quotes a randomised controlled double 
blind trial which shows no such effect.[3] Of more concern, however, 
is the fact that although large randomised controlled trials are 
clearly lacking in the context of fluid resuscitation in major burns, 
evidence demonstrating actual harm with hydroxyethyl starches 
(HESs), albeit from the general critical care literature, should be 
acknowledged. [4,5] Haase and Perner[6] stated that there is ‘no clear 
evidence for an overall beneficial effect of HES in any subgroup 
of critically-ill patients, but there are clear signs of harm’. These 
include adverse effects on renal and haemostatic function, with 
trends towards increased mortality. They recommended that its use 
be discontinued in these patients.
An international survey revealed that a considerable percentage 
of burn surgeons introduce albumin to their initially crystalloid-
based resuscitation within the 1st 24 hours post burn.[7] Albumin 
facilitates adequate resuscitation with significantly less fluid in 
the initial 24 hours after burn injury. While unlikely to reduce the 
initial extravasation of fluid into the interstitium, as a result of the 
capillary permeability in the burn wound itself, albumin does appear 
to ameliorate the impact of the reduced colloid osmotic pressure in 
unburnt tissues and notably in the lung, manifesting as reduced ‘fluid 
creep’, ventilatory requirements, and ultimately, mortality.[8,9] In light 
of the best available evidence, I encourage the author to reconsider 
his staunch advocacy for synthetic colloids, and especially HESs, and 
instead make use of 5% albumin as a ‘rescue’ measure in the specific 
context of major burn resuscitation. 
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Den Hollander responds: Many thanks for allowing me to res pond 
to the above letter. The conclusion of my original letter was that 
although the scales are starting to tip in favor of hydroxyethyl starches 
(HESs), there is very little level 1 evidence for its effectiveness in 
burns, and until such evidence is available, decisions regarding its 
use should be left to the experts who regularly care for such complex 
cases.[1] Too often, decisions are forced onto them by those with 
little insight into the evidence and Roger’s argument is no exception. 
The study by Béchir et al..[2] is, despite its title, not a randomised 
controlled trial (RCT) but – as I pointed out in my letter – a post-hoc 
analysis 10 years later of the 30 burn patients included in the Volume 
Substitution and Insulin Therapy in Severe Sepsis (VISEP) study. [3] 
The latter was indeed an RCT, but a post-hoc analysis of an RCT 
is not itself an RCT. Although the Béchir study showed no effect of 
HESs over saline, there are major methodological problems with this 
study, not least of which the fact that the HES-treated group was more 
severely injured than the saline group. Rogers subsequently advised 
me to ‘acknowledge evidence demonstrating actual harm with HES’, 
quoting in support the crystalloid v. HES CHEST study and Vlachou’s 
work, both of which were referenced in my letter. The CHEST 
study,[4] like the VISEP study,[3] has been severely criticised, recently 
again by Weisskopf and James,[5] who concluded that they both 
contain ‘important methodological and interpretative flaws’. They 
also contained mainly patients in septic shock, and results could not 
be applied to other patient populations. In these studies, the HES was 
administered not as a resuscitation fluid but as a daily supplement for 
several weeks. There are now 59 RCTs in surgical patients, totaling 
nearly 5 000 patients, showing a benefit in blood loss and transfusion 
requirements without any reported increase in adverse effects.[6-8] A 
single RCT in trauma showed a more rapid lactate clearance and a 
lower incidence of renal injury in patients resuscitated by HESs.[9]
Rogers would do well to remember recent history. It was not so 
long ago that albumin was blamed for the same adverse events as 
HESs are now – renal failure and an increased mortality – until 
the Saline v. Albumin Fluid Evaluation (SAFE) study[10] demon-
strated otherwise. It is also good to remember that the SAFE study 
reported no survival benefit of albumin over saline in their study 
population. A recent meta-analysis of albumin use in burns[11] 
concluded that albumin administration was associated with lower 
mortality and decreased risk of abdominal compartment syndrome 
than resuscitation with crystalloids only. However, this study 
cannot be used to justify a preference of albumin over HESs. 
Indeed, Vlachou[12] in a small RCT (26 patients) reached the same 
conclusions regarding HESs. These benefits seem to be rather 
effects of colloid over crystalloid resuscitation than evidence on 
which to base a choice between colloids. Other reviews of the use 
of albumin in burns and trauma resuscitation have confirmed the 
lack of untoward effects, but evidence of benefit has been harder to 
come by.[13-19]
In the basic science literature, our understanding of the micro-
circulation and the mechanisms responsible for oedema formation 
are radically changing, centreing on the role of the glycocalyx. [20] 
That colloid osmotic pressure does not play the role it was assigned 
by Ernest Starling is known to many burn surgeons, as burn 
oedema usually resolves in the face of dropping albumin levels. The 
mechanism responsible for ‘leaky capillaries’ seems to be not so 
much gaps that occur between endothelial cells, but rather a defective 
glycocalyx. One aim of resuscitation should be maintenance and 
restoration of the glycocalyx. The effects of various resuscitation 
fluids on the glycocalyx are still being worked out. Although albumin 
is an important constituent of the glycocalyx, experimental work has 
revealed that this structure is saturated with albumin at a plasma-
albumin level of as little as a quarter of physiological levels.[21] It may 
turn out that that plasma would be the ideal resuscitation fluid, as it 
has been shown to restore damaged glycocalyx in rats,[22] probably 
as a result of its ability to replenish glycosaminoglycans, an essential 
component of the glycocalyx. These studies are, however, still very 
much in the preclinical stage. Furthermore, plasma is expensive and 
carries risks. Under these circumstances the choice of which colloid 
to use should be left to the clinician. If Rogers prefers albumin for 
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burns resuscitation, he may, as long as he realises that it is just that, 
a preference. 
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